EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

CD24 targeting with NK‐CAR immunotherapy in testis, prostate, renal and (luminal‐type) bladder cancer and identification of direct CD24 interaction partners

Christian Söhngen, David J Thomas, Margaretha A Skowron iD, Felix Bremmer iD, Markus Eckstein iD, Anja Stefanski iD, Marc D Driessen iD, Gamal A Wakileh iD, Kai Stühler iD, Peter Altevogt iD, Dan Theodorescu iD, Rüdiger Klapdor iD and 2 more

The FEBS Journal · 2023

DOI: 10.1111/febs.16880 ↗

At a glance

Journal article in The FEBS Journal, 2023. Written by Christian Söhngen and 13 co-authors. Institution: Department of Urology, Urological Research Laboratory, Translational UroOncology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine …. Major MEDLINE topics: Receptors, Chimeric Antigen, Urogenital Neoplasms. Cited 19 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NCI NIH HHS, Deutsche Forschungsgemeinschaft, Deutsche Gesellschaft für Urologie.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Alternative therapeutic options targeting urologic malignancies, such as germ cell tumours, as well as urothelial, renal and prostate carcinomas, are still urgently needed. The membrane protein CD24 represents a promising immunotherapeutical approach. The present study aimed to decipher the molecular function of CD24 in vitro and evaluate the cytotoxic capacity of a third‐generation natural killer (NK) cell chimeric antigen receptor (CAR) against CD24 in urologic tumour cell lines. Up to 20 urologic tumour cell lines and several non‐malignant control cells were included. XTT viability assays and annexin V/propidium iodide flow cytometry analyses were performed to measure cell viability and apoptosis rates, respectively. Co‐immunoprecipitation followed by mass spectrometry analyses identified direct interaction partners of CD24. Luciferase reporter assays were used to functionally validate transactivation of CD24 expression by SOX2. N ‐ and O ‐glycosylation of CD24 were evaluated by enzymatic digestion and mass spectrometry. The study demonstrates that SOX2 transactivates CD24 expression in embryonal carcinoma cells. In cells of different urological origins, CD24 interacted with proteins involved in cell adhesion, ATP binding, phosphoprotein binding and post‐translational modifications, such as histone acetylation and ubiquitination. Treatment of urological tumour cells with NK‐CD24‐CAR cells resulted in a decreased cell viability and apoptosis induction specifically in CD24 + tumour cells. Limitations of the study include the in vitro setting, which still has to be confirmed in vivo . In conclusion, we show that CD24 is a promising novel target for immune therapeutic approaches targeting urologic malignancies.

Subjects

MeSH terms (MEDLINE)

Receptors, Chimeric AntigenUrogenital NeoplasmsHumansMaleCD24 AntigenCell Line, TumorImmunotherapyKiller Cells, NaturalProstateReceptors, Natural Killer CellTestisUrinary Bladder NeoplasmsUrologic Neoplasms

Author keywords

CD24immunotherapytesticular germ cell tumoururologic malignancies

Substances

CD24 AntigenCD24 protein, humanReceptors, Chimeric AntigenReceptors, Natural Killer Cell

Authors and institutions

  • Department of Urology, Urological Research Laboratory, Translational UroOncology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Germany.
  • Institute of Pathology, University Medical Center Goettingen, Germany.
  • Institute of Pathology, Friedrich Alexander University Erlangen-Nürnberg, University Hospital, Germany.
  • Molecular Proteomics Laboratory, Heinrich-Heine-University Düsseldorf, Germany.
  • Department of Urology, University Hospital Ulm, Germany.
  • Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID profiles: Margaretha A Skowron, Felix Bremmer, Markus Eckstein, Anja Stefanski, Marc D Driessen, Gamal A Wakileh, Kai Stühler, Peter Altevogt, Dan Theodorescu, Rüdiger Klapdor, Axel Schambach, Daniel Nettersheim

Funding

  • NCI NIH HHS
  • Deutsche Forschungsgemeinschaft
  • Deutsche Gesellschaft für Urologie
  • National Institutes of Health
  • Studienstiftung des Deutschen Volkes
  • Wilhelm Sander-Stiftung

Cite

APA

Söhngen, C., Thomas, D. J., Skowron, M. A., Bremmer, F., Eckstein, M., Stefanski, A., Driessen, M. D., Wakileh, G. A., Stühler, K., Altevogt, P., Theodorescu, D., Klapdor, R., Schambach, A., & Nettersheim, D. (2023). CD24 targeting with NK‐CAR immunotherapy in testis, prostate, renal and (luminal‐type) bladder cancer and identification of direct CD24 interaction partners. The FEBS Journal. https://doi.org/10.1111/febs.16880

Vancouver

Söhngen C, Thomas DJ, Skowron MA, Bremmer F, Eckstein M, Stefanski A, et al. CD24 targeting with NK‐CAR immunotherapy in testis, prostate, renal and (luminal‐type) bladder cancer and identification of direct CD24 interaction partners. The FEBS Journal. 2023. doi:10.1111/febs.16880

BibTeX
@article{Shngen2023,
  author = {Söhngen, Christian and Thomas, David J and Skowron, Margaretha A and Bremmer, Felix and Eckstein, Markus and Stefanski, Anja and Driessen, Marc D and Wakileh, Gamal A and Stühler, Kai and Altevogt, Peter and Theodorescu, Dan and Klapdor, Rüdiger and Schambach, Axel and Nettersheim, Daniel},
  title = {CD24 targeting with NK‐CAR immunotherapy in testis, prostate, renal and (luminal‐type) bladder cancer and identification of direct CD24 interaction partners},
  journal = {The FEBS Journal},
  year = {2023},
  doi = {10.1111/febs.16880}
}
Start for free →